A key driver of the Mineral Supplements Market is the increasing cancer prevalence supporting growth in the minimal residual disease testing market
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Minimal Residual Disease Testing Market From 2026 To 2030?
The minimal residual disease testing market has experienced rapid expansion in recent years. It is projected to increase from $1.8 billion in 2025 to $2.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. The growth observed in the historic period can be attributed to the growing prevalence of hematological malignancies, advancements in molecular diagnostic technologies, rising awareness about minimal residual disease, increasing adoption of precision medicine, and supportive government healthcare initiatives.
The minimal residual disease testing market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This projected growth can be linked to several factors, including advancements in technologies such as nGS and digital PCR, an increase in funding for cancer research, growing partnerships between diagnostic and pharmaceutical firms, a heightened need for personalized treatment monitoring, and improvements in healthcare infrastructure within emerging markets. Key trends expected during this period involve the increasing adoption of liquid biopsy, customized cancer monitoring, enhancements in early detection and prognosis, the incorporation of molecular diagnostics, and the broadening of oncology research.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Minimal Residual Disease Testing Market?
The expanding occurrence of cancer is projected to drive the future expansion of the minimal residual disease testing market. Cancer is defined as a state where some cells within the body multiply uncontrollably and disseminate to other areas. Minimal residual disease testing, an extremely sensitive technique for identifying cancer cells in humans, serves as the main approach for detecting cancer stages. This enables individuals with cancer to prevent the illness early, thereby stimulating the minimal residual disease testing market. As an illustration, the National Institutes of Health (NIH), a U.S.-based government agency, indicated in January 2023 that for the year 2023, 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the United States. Consequently, the rising occurrence of cancer is fueling the expansion of the minimal residual disease testing market.
Which Segments Are Included In The Analysis Of The Minimal Residual Disease Testing Market?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
Which Trends Are Impacting The Growth Of The Minimal Residual Disease Testing Market?
Leading companies in the minimal residual disease testing market are launching cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches for better patient outcomes. The IDT Archer FUSIONPlex Core Solid Tumor Panel refers to a targeted next-generation sequencing assay used for detecting gene fusions and mutations in solid tumors, aiding in precision oncology and treatment decision-making. For instance, in April 2023, Integrated DNA Technologies (IDT), a US-based provider of genomic solutions, launched the IDT Archer FUSIONPlex Core Solid Tumor Panel, an enhanced cancer research testing solution, now offering expanded and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay simplifies fusion detection and variant calling in solid tumors, utilizing a single sample input and offering researchers a scalable, user-friendly solution that saves time, resources, and costs.
Which Key Industry Participants Are Active In The Minimal Residual Disease Testing Market?
Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Read the full minimal residual disease testing market report here:
What Are The Leading Geographic Regions In The Minimal Residual Disease Testing Market?
North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Minimal Residual Disease Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp
Browse Through More Reports Similar to the Global Minimal Residual Disease Testing Market 2026, By The Business Research Company
Minimal Residual Disease Testing Market Report 2026
Rare Disease Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Infectious Disease Diagnostics Testing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
